<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04828512</url>
  </required_header>
  <id_info>
    <org_study_id>CR 313032</org_study_id>
    <nct_id>NCT04828512</nct_id>
  </id_info>
  <brief_title>Subclinical Diabetes Confirmed by 75gm-OGTT Influence on the Prognosis of Decompensated Cirrhosis</brief_title>
  <official_title>Subclinical Diabetes Confirmed by 75gm-OGTT Influence on the Prognosis of Decompensated Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Disorders of glucose metabolism, such as impaired glucose intolerance (IGT) and diabetes&#xD;
      mellitus (DM), frequently occur in cirrhosis. However, it has been underestimated when&#xD;
      fasting plasma glucose (FPG) levels are considered. We aimed to evaluate who needs to be&#xD;
      undertaken a 75-g oral glucose tolerance test (OGTT) to find underlying subclinical diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2, 2007</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Actual">January 30, 2014</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>42 Months</target_duration>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>Overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>major complications of cirrhosis</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>hepatic encephalopathy (HE), the development of spontaneous bacterial peritonitis (SBP), acute kidney injury (AKI), variceal bleeding, and infection</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1015</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>normal glucose tolerance (NGT)</arm_group_label>
    <description>In the 75-g OGTT, an FPG level of &lt; 100 mg/dL or a 120-min PG level of &lt; 140 was diagnosed as NGT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>impaired glucose intolerance (IGT)</arm_group_label>
    <description>In the 75-g OGTT, an FPG level of 100-125 mg/dL (5.6-6.9 mmol/L) or a 120-min PG level of 140-200 mg/dL (7.8-11.1 mmol/L) was diagnosed as IGT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>newly diagnosed DM (subclinical DM)</arm_group_label>
    <description>In the 75-g OGTT, a basal FPG level ˃126 mg/dL (7.0 mmol/L) or a 120-min PG level ˃200 mg/dL (11.1 mmol/L) was considered as newly diagnosed DM (hereafter referred to as subclinical DM).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with cirrhosis without previous diabetes history&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Liver cirrhosis&#xD;
&#xD;
          -  Admitted to a hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously confirmed DM&#xD;
&#xD;
          -  Being treated for DM&#xD;
&#xD;
          -  Standard risk factors of T2DM, such as high body mass index and family history of&#xD;
             diabetes&#xD;
&#xD;
          -  Symptoms of DM, such as increased thirst and the need to urinate&#xD;
&#xD;
          -  Either hepatocellular carcinoma or other malignancy&#xD;
&#xD;
          -  Hepatic failure or uncontrolled decompensation [that is, refractory ascites or active&#xD;
             variceal hemorrhage]&#xD;
&#xD;
          -  Significant illnesses such as sepsis that may have interfered with glucose metabolism&#xD;
&#xD;
          -  Pancreatic dysfunction such as acute/chronic pancreatitis that may have affected&#xD;
             glucose metabolism.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

